Back to top

Image: Bigstock

NeuBase (NBSE) in Focus: Stock Moves 5.6% Higher

Read MoreHide Full Article

NeuBase Therapeutics, Inc. (NBSE - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $7.49 to $8.28 in the past one-month time frame.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

NeuBase currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Ohr Pharmaceuticals, Inc. Price

Investors interested in the Medical - Biomedical and Genetics industry may consider Akcea Therapeutics, Inc. (AKCA - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!  

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. 

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.  

Click here for the 6 trades >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Akcea Therapeutics, Inc. (AKCA) - free report >>

Ohr Pharmaceuticals, Inc. (NBSE) - free report >>